Trial
Menarini European phase 3 (NCT07614958)
Status Recruiting; primary completion January 2027
A 426-patient phase 3 study started May 2026 by Menarini, obicetrapib's European partner, with primary completion January 2027. Part of the European launch programme rather than the pivotal file.
Worth tracking mainly as a signal of commercial intent: the European partner started a new phase 3 two months before the CHMP opinion.
Page updated 18 August 2026.